Shuttle Pharmaceuticals (SHPH) announced the pricing of its “reasonable best efforts” public offering with a health-care focused institutional investor for the purchase and sale of up to 2,950,820 shares of common stock and warrants to purchase up to 2,950,820 shares of common stock at a combined offering price of $1.525 per share and accompanying warrant, priced at-the-market under Nasdaq rules. The Company expects to receive aggregate gross proceeds of approximately $4.5 million, before deducting placement agent fees and other offering expenses, and assuming no exercise of the warrants. The warrants will have an exercise price of $1.40 per share, will be exercisable immediately and will expire five years from the issuance date. A.G.P./Alliance Global Partners is acting as the lead placement agent for the Offering and Boustead Securities, LLC is acting as a co-placement agent for the Offering.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on SHPH:
- Shuttle Pharmaceuticals Advances Phase 2 Glioblastoma Trial
- Shuttle Pharmaceuticals doses first patients in Phase 2 trial of Ropidoxuridine
- Shuttle Pharmaceuticals Advances Glioblastoma Clinical Trials
- Shuttle’s clinical trial site enrollments complete for Phase 2 of IPdR for GBM
- Shuttle Pharmaceuticals to Present at ThinkEquity Conference
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
